[
    [
        {
            "time": "",
            "original_text": "医药生物行业周报：基因细胞治疗CDMO黄金赛道有望孕育下一个药明生物",
            "features": {
                "keywords": [
                    "医药生物",
                    "基因细胞治疗",
                    "CDMO",
                    "黄金赛道",
                    "药明生物"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：基因细胞治疗CDMO黄金赛道有望孕育下一个药明生物",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "生物医药行业周报：新冠疫苗相继获批上市 密切关注一季度业绩",
            "features": {
                "keywords": [
                    "生物医药",
                    "新冠疫苗",
                    "获批上市",
                    "一季度业绩"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "生物医药行业周报：新冠疫苗相继获批上市 密切关注一季度业绩",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "CXO行业无海外订单回流风险，龙头业绩向好 调整后估值优势凸显",
            "features": {
                "keywords": [
                    "CXO",
                    "海外订单",
                    "回流风险",
                    "龙头业绩",
                    "估值优势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CXO行业无海外订单回流风险，龙头业绩向好 调整后估值优势凸显",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]